Artivion Senior Vice President Andrew Green sold $17,586 of common stock on August 14, 2026. The transaction involved the disposition of 616 shares at a price of $28.549 per share. According to the filing, these shares were sold upon the vesting of restricted stock units to cover tax withholding obligations.
Following this transaction, Mr. Green directly holds 59,643 shares of Artivion common stock. The company's shares have posted a significant return of nearly 11% over the past week. Artivion recently reported second-quarter revenue of $125.8 million, marking a 9% increase on a constant-currency basis. The growth was driven by strong performance in stent grafts and On-X heart valves.
Recent Developments
Artivion's acquisition of Endospan and the PMA approval for AMDS were highlighted as significant developments by Canaccord, which raised its price target for the company from $36 to $39 while maintaining a Buy rating. These recent achievements suggest a positive outlook for Artivion, according to Canaccord's analysis.